A more efficient DNA technology to detect and treat infectious diseases and cancer has been developed by researchers at the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR.
The researchers improved on existing technologies to create a modified single-stranded DNA molecule called aptamer. DNA aptamers are ideal for pharmaceutical applications because they can specifically bind to any molecular target in the body such as proteins, viruses, bacteria and cells.
Once DNA aptamers are artificially generated for each target, they will bind to it and inhibit its activity. This makes DNA aptamers a promising technology for disease detection and drug delivery. But no DNA aptamers have been approved for clinical use yet because current aptamers do not bind well to molecular targets and are easily digested by enzymes.
“To overcome these challenges, we have created a DNA aptamer with strong binding ability and stability with superior efficacy. We hope to use our DNA aptamers as the platform technology for diagnostics and new drug development,” said IBN Executive Director Professor Jackie Y. Ying.
This study, led by IBN Principal Research Scientist and Team Leader Dr Ichiro Hirao, was recently published in the journal, Scientific Reports.
To tackle the weak binding problem, the research team added a new artificial component called unnatural base to a standard DNA aptamer, which typically has four components. The addition of the fifth component greatly enhanced the binding ability to the molecular target by 100 times as compared to conventional DNA aptamers. Furthermore, to prevent the aptamer from being digested easily by enzymes, a unique and small DNA called ‘mini-hairpin DNA’ was added to the DNA aptamer.
Dr Hirao explained, “The mini-hairpin DNAs have an unusually stable and compact stem-loop structure, like a hairpin, of small DNA fragments. Their structure strongly resists the digestive enzymes, so I added them to specific positions on the DNA aptamer to act as a protective shield. Usually DNAs are digested within one hour in blood at body temperature. With the mini-hairpin DNA, our DNA aptamers can survive for days instead of hours. This is important for pharmaceutical applications, which require the therapeutic to remain in the body for a longer period.”
If successfully commercialized, DNA aptamers could replace or complement the existing use of antibodies in drugs for targeted disease treatment. Like aptamers, antibodies bind to targets in the body, but often cause undesirable immune response and are not easy to mass produce with high quality.
“We can now generate very promising DNA aptamers for clinical use. Our aptamers are more efficient, and lower in cost and toxicity compared to conventional methods. The next step of our research is to use the aptamers to detect and deactivate target molecules and cells that cause infectious diseases, such as dengue, malaria and Methicillin-resistant Staphylococcus aureus, as well as cancer,” added Dr Hirao.
The Latest on: DNA technology
via Google News
The Latest on: DNA technology
- 40-Year-Old Cold Case Killing of Aspiring Journalist Helene Pruszynski Is Solved Thanks to New Technologyon April 19, 2021 at 1:30 pm
Helene Pruszynski was a student attending Wheaton College in Massachusetts when she moved to Colorado to work as an intern at a Denver radio station. She was on her way to a relative's house after ...
- DNA Diagnostics Market Research Report, Analysis, Covid-19 Analysis, Industry Scope, Global Opportunity Analysis and Industry Forecast Till 2027on April 19, 2021 at 7:39 am
DNA diagnostics Market Report published by Allied Market Research forecasts that the global market is expected to garner 19 billion by 2027 registering a CAGR of 9 8 during the period 2014 2027 The ...
- PFU America, Inc. Joins DNA Data Storage Allianceon April 19, 2021 at 6:00 am
PFU America, Inc., based in Sunnyvale, California, a member of the PFU group of companies, announced it joined the DNA Data Storage Alliance, ...
- Aegis and Entos commence dosing in trial of Covid-19 DNA vaccineon April 19, 2021 at 3:19 am
US company Aegis Life has initiated dosing of the first participants in a Phase I/II clinical trial with parent company Entos Pharmaceuticals’ novel DNA Covid-19 vaccine, Covigenix VAX-001, to induce ...
- Novel CRISPR-based technology may lead to powerful epigenetic therapieson April 18, 2021 at 12:39 pm
Scientists have figured out how to modify CRISPR's basic architecture to extend its reach beyond the genome and into what's known as the epigenome -- proteins and small molecules that latch onto DNA ...
- DNA tech, unsealed adoption records lead to family reunion for Fairfield HS gradon April 18, 2021 at 3:18 am
Findings like McCoy’s and Centerville resident Beth Miller, who was adopted at birth, are becoming more common with DNA technology and an Ohio law unsealing adoption records, a state adoption ...
- Global Recombinant DNA Technology Market Analysis 2016-2020 and Forecast 2021-2026on April 17, 2021 at 1:02 am
Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):by Productby Types GET FREE ...
- North America DNA Sequencing Market - Economic Conditions, Acquisitions, Mergers, Developments and Forecaston April 15, 2021 at 4:44 am
According to a new report published by Research Dive titled North America DNA Sequencing Market by product application technology and end user Opportunity Analysis and Industry Forecast 2019 2025 the ...
- Recombinant DNA Technology Market Insight, Share, Competitive Analysis by 2026on April 13, 2021 at 9:15 pm
The Global Recombinant DNA Technology Market will grow considerably in the coming years due to exceptional scientific advancements in gene therapy. According to a report by Fortune Business Insights, ...
- Fact Check-mRNA vaccines do not turn humans into ‘hybrids’ or alter recipients’ DNAon April 13, 2021 at 6:55 am
Contrary to claims on social media, COVID-19 vaccines using messenger RNA (mRNA) technology do not transform recipients from humans into “hybrids,” nor do they alter human DNA through nanotechnology.
via Bing News